Pfizer maps post-Covid reset with obesity trials and deep cost cuts
Pfizer reported fourth-quarter results that beat expectations, offering a steadier earnings picture as the company moves further away from the Covid-driven revenue surge of recent years. While demand for its pandemic-era products continues to fade, the pharmaceutical group is refocusing its strategy around pipeline development, targeted acquisitions, and large-scale cost reductions. The latest earnings update
